menu
    • menu
    [{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nalbuphine Sebacate","moa":"narcotic agonists\/antagonists (normorphine type)","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lumosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lumosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sinew Pharma Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nalbuphine Sebacate","moa":"narcotic agonists\/antagonists (normorphine type)","graph1":"Neurology","graph2":"Phase II","graph3":"Sinew Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sinew Pharma Inc. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sinew Pharma Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nalbuphine Sebacate","moa":"narcotic agonists\/antagonists (normorphine type)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lumosa Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Nalbuphine Sebacate

    Menu

    Nalbuphine Sebacate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sinew Pharma Inc.

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Sinew Pharma Inc.

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Sebacate

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Manag...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 06, 2023

                            Lead Product(s) : Nalbuphine Sebacate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lumosa Therapeutics

                            Taiwan arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Lumosa Therapeutics

                            Taiwan arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Sebacate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's ...

                            Details : LT1001 is the world's first week-long extended-release analgesic injection. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 21, 2020

                            Lead Product(s) : Nalbuphine Sebacate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lumosa Therapeutics

                            Taiwan arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Lumosa Therapeutics

                            Taiwan arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Sebacate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 05, 2020

                            Lead Product(s) : Nalbuphine Sebacate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lumosa Therapeutics

                            Taiwan arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Lumosa Therapeutics

                            Taiwan arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Sebacate

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 10, 2015

                            Lead Product(s) : Nalbuphine Sebacate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth